Pfizer invites applications for its pre-clinical and translational research in multiple myeloma call. This supports pre-clinical projects with a focus on multiple myeloma. The following areas are of particular interest:
•exploring the predictive impact of biological mechanisms in response or refractoriness to and relapse after anti-B-cell maturation antigen treatment;
•preclinical predictive model and evaluation of biological heterogeneity for minimisation of toxicity, with particular focus on cytokine release syndrome;
•expanding development, use and application of computational analysis, artificial intelligence, machine learning in MM setting, with particular focus on anti-BCMA pathways.
Only organisations are eligible to receive grants. The institution and PI must be based in Italy. The PI must have a medical or postdoctoral degree. Applicants must be affiliated with a host institution.
Grants are worth up to USD 100,000 per project over up to two years. The total budget is USD 300,000.
Deadline: 18th May 2022.